Post-Conference Perspectives: Updates in HER2+ Metastatic Breast Cancer; ASCO 2023 Highlights

home / news-network / post-conference-perspectives-updates-in-her2-metastatic-breast-cancer-asco-2023-highlights

Megan Kruse, MD, reviews updates from the 2023 ASCO Annual Meeting and offers insights onthe evolving treatment landscape for HER2+ metastatic breast cancer.

Megan Kruse, MD, an expert on breast cancer

EP. 1: Evolving Treatment Strategies for HER2+ Metastatic Breast Cancer

By Megan Kruse, MD, of Cleveland Clinic

June 29th 2023

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

EP. 2: Data Updates from SABCS 2022 in HER2+ Metastatic Breast Cancer

By Megan Kruse, MD, of Cleveland Clinic

June 29th 2023

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

EP. 3: Updates from ASCO 2023 in HER2+ Metastatic Breast Cancer

By Megan Kruse, MD, of Cleveland Clinic

July 6th 2023

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

EP. 4: Treating HER2+ Breast Cancer with CNS Involvement

By Megan Kruse, MD, of Cleveland Clinic

July 6th 2023

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

EP. 5: HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

By Megan Kruse, MD, of Cleveland Clinic

July 13th 2023

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.